Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT01348126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
Study identification
- NCT ID
- NCT01348126
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 385 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2011
- Primary completion
- Mar 31, 2014
- Completion
- Sep 30, 2015
- Last update posted
- Nov 4, 2015
2011 – 2015
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Synta Pharmaceuticals Investigative Site | Tucson | Arizona | 85715 | — |
| Synta Pharmaceuticals Investigative Site | Santa Monica | California | 90404 | — |
| Synta Pharmaceuticals Investigative Site | Atlanta | Georgia | 30322 | — |
| Synta Pharmaceuticals Investigative Site | Chicago | Illinois | 60637 | — |
| Synta Pharmaceutials Investigative Site | Boston | Massachusetts | 02215 | — |
| Synta Pharmaceuticals Investigative Site | Winston-Salem | North Carolina | 27103 | — |
| Synta Pharmaceuticals Investigative Site | Kettering | Ohio | 45429 | — |
| Synta Pharmaceuticals Investigative Site | Portland | Oregon | 97227 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01348126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2015 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01348126 live on ClinicalTrials.gov.